BioCentury
ARTICLE | Company News

Alfa Wassermann, Norgine sales and marketing update

March 30, 2015 7:00 AM UTC

The U.K.’s NICE issued final guidance recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of episodes of overt hepatic encephalopathy (HE) in adults -- its approved indication in the EU. The guidance is in line with a final appraisal determination (FAD) issued in February (see BioCentury, Feb. 23). ...